uniQure B.V. Aktie 23539614 / NL0010696654
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
|
24.09.2025 19:50:04
|
UniQure Stock Soars 234% On Positive Huntington's Disease Trial Data
(RTTNews) - uniQure N.V. (QURE) shares skyrocketed 234.17 percent to $45.80 on Wednesday, jumping $32.14, after the company reported positive topline results from its pivotal Phase I of II study of AMT-130 for the treatment of Huntington's disease.
The stock opened at $39.20 and traded between $37.12 and $47.37, compared with a prior close of $13.66 on the Nasdaq.
Trading volume surged to 42.0 million shares, far exceeding the average of 1.1 million. uniQure now trades within a 52-week range of $4.45 to $47.37, touching the top of its range.
The trial met its primary endpoint, with high-dose AMT-130 showing a statistically significant slowing of disease progression at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale, compared with matched external controls.
Nachrichten zu uniQure B.V.
|
24.09.25 |
uniQure-Aktie klettert um 266 Prozent: Huntington-Erfolg beflügelt (finanzen.ch) | |
|
28.07.25 |
Ausblick: Uniqure BV zieht Bilanz zum jüngsten Jahresviertel (finanzen.net) | |
|
08.05.25 |
Ausblick: Uniqure BV präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net) |